Can Ceftriaxone Cause Cholestasis?
Yes, ceftriaxone can cause cholestasis, though it is a rare adverse effect that typically manifests as self-limited cholestatic or mixed hepatitis occurring 1-3 weeks after administration, even following a single dose.
Mechanism and Clinical Presentation
Ceftriaxone-induced cholestasis occurs through biliary precipitation and potential hepatocellular injury. The FDA label explicitly warns about ceftriaxone-calcium precipitates in the gallbladder that can lead to biliary obstruction and secondary cholestatic injury 1. Additionally, ceftriaxone can cause direct drug-induced liver injury (DILI) with a cholestatic pattern 2.
The clinical presentation typically includes:
- Latency period: 1-3 weeks after drug exposure, even after a single dose
- Biochemical pattern: Mixed or cholestatic (alkaline phosphatase >2x ULN or ALT/AP ratio <2)
- Symptoms: Jaundice, fatigue, pruritus
- Course: Generally self-limited after drug discontinuation 2, 3
Evidence Quality and Strength
The most recent high-quality evidence comes from the 2025 Drug-Induced Liver Injury Network (DILIN) study, which identified 3 cases of ceftriaxone-induced DILI among 1,854 adjudicated cases 2. This study demonstrated that cephalosporin-induced liver injury presents with a mixed or cholestatic biochemical pattern and is associated with HLA-A*02:01 allele, suggesting genetic susceptibility.
The FDA drug label confirms multiple cholestatic complications 1:
- Gallbladder pseudolithiasis with biliary sludge
- Pancreatitis possibly secondary to biliary obstruction
- Hepatic dysfunction including cholestasis (listed as a cephalosporin class effect)
- Elevations in alkaline phosphatase and bilirubin
Risk Factors and Special Populations
Pediatric patients appear at higher risk for ceftriaxone-related biliary complications 1, 3, 4, 5. One prospective study found 46.5% of children developed sonographic evidence of cholelithiasis after ≥10 days of treatment, with 2 showing intrahepatic cholestasis 4.
Patients with sickle cell disease may develop marked conjugated hyperbilirubinemia with ceftriaxone, as documented in a case where total bilirubin increased from 3.3 to 17 mg/dL 6.
Patients with pre-existing liver disease warrant particular caution. The FDA label states that in patients with both hepatic dysfunction and significant renal disease, ceftriaxone dosage should not exceed 2 grams daily 1.
Clinical Management Algorithm
Detection:
- Monitor liver biochemistries (alkaline phosphatase, bilirubin, transaminases) in patients receiving prolonged ceftriaxone therapy
- Obtain abdominal ultrasound if cholestatic pattern develops to assess for biliary sludge/stones 7, 1
- Calculate R value using baseline values if underlying liver disease present 8
Diagnosis:
Drug-induced cholestasis diagnosis requires 7:
- Temporal relationship between ceftriaxone exposure and symptom onset
- Exclusion of other causes (viral hepatitis, biliary obstruction, autoimmune disease)
- Liver biopsy is not mandatory unless severe, progressive, or prolonged course
Treatment:
Immediate discontinuation of ceftriaxone is the only effective treatment 7. The EASL guidelines explicitly state there is no effective treatment for drug-induced cholestasis except withdrawal 7.
Additional management:
- Monitor liver biochemistries until normalization (typically within 3 months) 7
- Ensure adequate hydration 1
- UDCA may be considered but is regarded as experimental 7
- Corticosteroids lack controlled trial evidence 7
Prognosis:
The outcome is generally good after drug withdrawal 7. Ceftriaxone-induced biliary precipitates and associated cholestasis are reversible upon discontinuation 1, 3, 4, 5.
Critical Pitfalls to Avoid
Do not rechallenge with ceftriaxone once cholestasis is identified—this is potentially harmful and unethical 7
Do not delay discontinuation while awaiting extensive workup. Prompt withdrawal is crucial to avoid serious liver injury 7
Do not assume biliary sludge is benign. While often asymptomatic, it can progress to symptomatic cholecystitis or pancreatitis 1, 5
Do not overlook the delayed presentation. Cholestasis can develop 1-3 weeks after even a single dose of ceftriaxone 2
Monitor prothrombin time in patients with chronic hepatic disease receiving ceftriaxone, as alterations can occur 1
The key clinical takeaway: Ceftriaxone-induced cholestasis is real but rare, typically self-limited, and requires immediate drug discontinuation as the primary intervention.